Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Elias Jabbour, Lakshmikanth Katragadda, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Alfonso Quintás-Cardama, M.D.

Blood (2012) 120 (21): 1687.

https://doi.org/10.1182/blood.V120.21.1687.1687

Published: 2012

Journal Articles

Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy

Christopher B. Benton, MD, Peng Qiu, PhD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, RN, BS, Anisha Borthakur, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD, Michael Andreeff, MD, PhD, Alfonso Quintás-Cardama, M.D.

Blood (2012) 120 (21): 1417.

https://doi.org/10.1182/blood.V120.21.1417.1417

Published: 2012

Journal Articles

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Koichi Takahashi, MD, Naveen Pemmaraju, M.D., Miloslav Beran, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Elias J. Jabbour, MD, Naval Daver, MD, Zeev Estrov, MD, PhD, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3797.

https://doi.org/10.1182/blood.V120.21.3797.3797

Published: 2012

Journal Articles

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Aziz Nazha, Hagop M. Kantarjian, MD, Preetesh Jain, MD, DM, PhD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, M.D., Rajyalakshmi Luthra, PhD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3757.

https://doi.org/10.1182/blood.V120.21.3757.3757

Published: 2012

Journal Articles

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Farhad Ravandi, Cielo Foudray, Naveen Pemmaraju, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Naval G. Daver, MD, Stefan Faderl, MD, Elias Jabbour, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3821.

https://doi.org/10.1182/blood.V120.21.3821.3821

Published: 2012

Journal Articles

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Rajyalakshmi Luthra, Ph.D., Alfonso Quintás-Cardama, M.D., Elias J. Jabbour, MD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 3781.

https://doi.org/10.1182/blood.V120.21.3781.3781

Published: 2012

Journal Articles

Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era

Young Kwang Chae, MD, MPH, Hagop M. Kantarjian, MD, Carlos G. Romo, M.D., Clay Whitaker, Elias J. Jabbour, MD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Farhad Ravandi, MD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 3786.

https://doi.org/10.1182/blood.V120.21.3786.3786

Published: 2012

Journal Articles

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Sherry A. Pierce, RN, BS, Moshe Talpaz, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 918.

https://doi.org/10.1182/blood.V120.21.918.918

Published: 2012

Journal Articles

Nomogram to Prognosticate Outcomes in Patients with Chronic Myeloid Leukemia At Any Time-Point During Tyrosine Kinase Inhibitor Therapy

Alfonso Quintás-Cardama, M.D., Xuelin Huang, PhD, Sangbum Choi, PhD, Hagop M Kantarjian, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 71.

https://doi.org/10.1182/blood.V120.21.71.71

Published: 2012

NARROW

Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience

Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Nomogram to Prognosticate Outcomes in Patients with Chronic Myeloid Leukemia At Any Time-Point During Tyrosine Kinase Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only